曲克芦丁脑蛋白水解物联合常规康复训练治疗小儿痉挛型脑性瘫痪的效果分析

Analysis of therapeutic effect of troxerutin cerebroprotein hydrolyzate on children with spastic cerebral palsy

摘要:

目的 探讨曲克芦丁脑蛋白水解物对小儿痉挛型脑性瘫痪康复治疗的效果。方法 选取2021年12月—2022年3月武汉市第一医院收治的痉挛型脑性瘫痪患儿72例，采用数字奇偶法分为对照组（给予常规康复训练）和观察组（给予常规康复训练+曲克芦丁脑蛋白水解物），每组36例。比较两组患儿治疗前后运动功能评分［粗大运动功能测试量表（GMFM）、精细运动能力测试量表（FMFM）评分］、步行能力、血清神经细胞因子水平［神经元特异性烯醇化酶（NSE）、脑源性神经细胞营养因子（BDNF）］、脑功能及不良反应。结果 观察组治疗前后GMFM、FMFM评分差值高于对照组（P <0.05）。观察组治疗前后10 m步行速度、6 min步行距离差值高于对照组（P <0.05）。观察组治疗前后NSE、BDN差值高于对照组（P <0.05）。观察组治疗前后θ波、β波及θ/β差值高于对照组（P <0.05）。两组患者不良反应发生率比较，差异无统计学意义（P >0.05）。结论 曲克芦丁脑蛋白水解物用于治疗小儿痉挛型脑性瘫痪可提高运动功能、步行能力及神经功能，改善脑功能，且安全可靠。

Abstract:

Objective To investigate the therapeutic effect of Troxerutin cerebroprotein hydrolysate on children with spastic cerebral palsy (SCP).Methods A total of 72 children with SCP admitted to our hospital from September 2020 to August 2021 were selected and divided into control group (given conventional rehabilitation training) and observation group (given conventional rehabilitation training + Troxerutin cerebral protein) by digital parity method hydrolyzate), 36 cases in each group. The motor function scores [gross motor function test scale (GMFM), fine motor ability test scale (FMFM) score], walking ability, serum neurocytokine levels [neuron-specific enolase (NSE) before and after treatment in the two groups of children, brain-derived neurotrophic factor (BDNF) ], brain function, and adverse reactions were compared.Results After treatment, the GMFM and FMFM scores of the two groups were increased (P < 0.05), and the GMFM and FMFM scores of the observation group were higher than those of the control group (P < 0.05). After treatment, the 10-m walking speed and 6-min walking distance in the two groups were increased (P < 0.05), and the 10-m walking speed and 6-min walking distance in the observation group were higher than those in the control group (P < 0.05). After treatment, the levels of NSE in the two groups were decreased (P < 0.05), while the levels of BDNF were increased (P < 0.05). After treatment, the level of NSE in the observation group was lower than that in the control group (P < 0.05), while the level of BDNF was higher than that in the control group (P < 0.05). After treatment, the θ wave and θ/β values of the two groups were decreased (P < 0.05), while the β wave was increased (P < 0.05). After treatment, the values of θ wave and θ/β in the observation group were lower than those in the control group (P < 0.05), and the β wave was higher than that in the control group (P < 0.05). The incidence of adverse reactions in the two groups was similar (P > 0.05).Conclusion Troxerutin cerebroprotein hydrolysate can improve motor function, walking ability and neurological function, improve brain function, and is safe and reliable for the treatment of children with SCP.